OM:ACARIX

Stock Analysis Report

Executive Summary

Acarix AB (publ), a medical technology company, develops and commercializes diagnostic tests for cardiovascular diseases.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.

Share Price & News

How has Acarix's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-40.8%

ACARIX

-1.0%

SE Medical Equipment

2.9%

SE Market


1 Year Return

-74.2%

ACARIX

26.1%

SE Medical Equipment

9.0%

SE Market

Return vs Industry: ACARIX underperformed the Swedish Medical Equipment industry which returned 26.1% over the past year.

Return vs Market: ACARIX underperformed the Swedish Market which returned 9% over the past year.


Share holder returns

ACARIXIndustryMarket
7 Day-40.8%-1.0%2.9%
30 Day-61.0%-0.05%-0.4%
90 Day-60.2%-7.0%0.3%
1 Year-61.8%-74.2%27.4%26.1%13.7%9.0%
3 Yearn/a44.1%26.9%30.5%11.1%
5 Yearn/a68.2%40.4%66.0%30.7%

Price Volatility Vs. Market

How volatile is Acarix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Acarix undervalued based on future cash flows and its price relative to the stock market?

0.66x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Undervalued: Insufficient data to calculate ACARIX's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate ACARIX's fair value to establish if it is undervalued.


Price Based on Earnings

PE vs Industry: ACARIX is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: ACARIX is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate ACARIX's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: ACARIX is good value based on its PB Ratio (0.7x) compared to the SE Medical Equipment industry average (4.4x).


Next Steps

Future Growth

How is Acarix expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

5.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Earnings vs Savings Rate: ACARIX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ACARIX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ACARIX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ACARIX's revenue (61.2% per year) is forecast to grow faster than the Swedish market (4.5% per year).

High Growth Revenue: ACARIX's revenue (61.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Estimates


Future Return on Equity

High Future ROE: Insufficient data to determine if ACARIX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Acarix performed over the past 5 years?

-15.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: ACARIX is unprofitable, and losses have increased over the past 5 years at a rate of -15% per year.

Accelerating Growth: Unable to compare ACARIX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ACARIX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (17.3%).


Return on Equity

High ROE: ACARIX has a negative Return on Equity (-78.54%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: ACARIX is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: ACARIX is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Acarix's financial position?


Financial Position Analysis

Short Term Liabilities: ACARIX's short term assets (SEK46.6M) exceeds its short term liabilities (SEK7.6M)

Long Term Liabilities: ACARIX's short term assets (46.6M) exceeds its long term liabilities (121.0K)


Debt to Equity History and Analysis

Debt Level: ACARIX is debt free.

Reducing Debt: ACARIX had no debt 5 years ago.


Balance Sheet

Inventory Level: ACARIX has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if ACARIX's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ACARIX has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ACARIX has less than a year of cash runway if free cash flow continues to reduce at historical rates of -18.1% each year


Next Steps

Dividend

What is Acarix's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.8%markettop25%4.8%industryaverage1.3%forecastin3Years0%

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate ACARIX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ACARIX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if ACARIX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ACARIX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ACARIX's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

What is the CEO of Acarix's salary, the management and board of directors tenure and is there insider trading?

3.8yrs

Average management tenure


CEO

Per Persson 0

0.9yrs

Tenure

kr2,966,000

Compensation

Mr. Per Persson has been the Chief Executive Officer of Acarix AB (publ) since November 13, 2018, and joined it in July 2018. He was Chief Commercial Officer at Acarix AB (publ) since August 2018 until Nov ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Per's total compensation is reasonable compared to companies of similar size in the Swedish market.

Compensation vs Earnings: Insufficient data to compare Per's compensation with company performance.


Management Age and Tenure

3.8yrs

Average Tenure

Experienced Management: ACARIX's management team is considered experienced (3.8 years average tenure).


Board Age and Tenure

4.3yrs

Average Tenure

55yo

Average Age

Experienced Board: ACARIX's board of directors are considered experienced (4.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Christian Lindholm (55yo)

    Chief Financial Officer

    • Tenure: 3.8yrs
    • Compensation: kr2.28m
  • Claus Bo Christensen (55yo)

    Chief Operating Officer

    • Tenure: 10.8yrs
  • Anja Schaefer

    Chief Marketing Officer

    • Tenure: 3.8yrs
  • Per Persson

    Chief Executive Officer

    • Tenure: 0.9yrs
    • Compensation: kr2.97m

Board Members

  • Johanne Brændgaard

    Director

    • Tenure: 4.8yrs
    • Compensation: kr118.00k
  • Werner Braun (73yo)

    Chairman of the Board

    • Tenure: 3.8yrs
    • Compensation: kr701.00k
  • Claus Andersson (51yo)

    Director

    • Tenure: 9.8yrs
    • Compensation: kr118.00k
  • Ulf Rosén (59yo)

    Director

    • Tenure: 5.8yrs
    • Compensation: kr118.00k
  • Hong Fei (39yo)

    Director

    • Tenure: 3.8yrs
    • Compensation: kr118.00k
  • Paolo Raffaelli

    Director

    • Tenure: 0.4yrs

Company Information

Acarix AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Acarix AB (publ)
  • Ticker: ACARIX
  • Exchange: OM
  • Founded: 2009
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr42.140m
  • Shares outstanding: 23.03m
  • Website: https://www.acarix.com

Number of Employees


Location

  • Acarix AB (publ)
  • World Trade Center
  • Skeppsgatan 19
  • Malmö
  • Skåne County
  • 211 11
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ACARIX BTA 1OM (OMX Nordic Exchange Stockholm)NPV BTA 122019SESEKNo data
ACARIXOM (OMX Nordic Exchange Stockholm)YesOrdinary SharesSESEKDec 2016
7ACDB (Deutsche Boerse AG)YesOrdinary SharesDEEURDec 2016

Biography

Acarix AB (publ), a medical technology company, develops and commercializes diagnostic tests for cardiovascular diseases. The company offers CADScor System for the diagnosis of coronary artery disease. It  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/11 22:52
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)